Actively Recruiting
Study of Romiplostim N01 to Improve Platelet Recovery After Haploidentical Stem Cell Transplant in Blood Cancer Patients
Led by First Affiliated Hospital of Zhejiang University · Updated on 2026-01-28
130
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of Romiplostim N01 in helping platelet recovery after haploidentical allogeneic hematopoietic stem cell transplantation haplo-HSCT for patients with blood cancers like acute myeloid leukemia AML and myelodysplastic syndromes MDS. This phase 1 randomized controlled study aims to see if Romiplostim N01 can improve platelet engraftment rates and reduce bleeding risks following transplant. Participants will be randomly assigned to one of two groups a treatment group receiving Romiplostim N01 as a weekly subcutaneous injection starting at 5 gkg with dose adjustments up to 10 gkg for up to 4 weeks or until platelet counts reach 100 x 10L, and a control group receiving standard supportive care without Romiplostim or other thrombopoietin receptor agonists. Both groups may receive transfusions and growth factors as needed. During the study, participants will be monitored for platelet engraftment up to 21 days post-transplant and other blood recovery markers over 4 to 60 days. Researchers will track platelet counts, transfusion volume, erythroid and neutrophil responses, and safety outcomes like adverse events and thromboembolic events. The study includes close follow-up to assess overall hematopoietic recovery and treatment safety throughout the post-transplant period.
CONDITIONS
Brief Title
Romiplostim N01 for Platelet Recovery After Haploidentical HSCT
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here